Inject and extend dosing versus dosing as needed: A comparative retrospective study of ranibizumab in exudative age-related macular degeneration

Retina

Volumn 31, Issue 1, 2011, Pages 26-30

  Oubraham, Hassiba ^a   Cohen, Salomon Y ^b,c   Samimi, Sepideh ^a   Marotte, David ^a   Bouzaher, Ines ^a   Bonicel, Pierre ^a   Fajnkuchen, Franck ^b   Tadayoni, Ramin ^c  

^a CENTRE HOSPITALIER   (France)

^b Centre Ophtalmologique d'Imagerie et de Laser   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

age related macular degeneration; antivascular endothelial growth factor; choroidal neovascularization; ranibizumab

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; FEMALE; FOLLOW UP; HUMAN; MALE; RANK SUM TEST; RETINA MACULA AGE RELATED DEGENERATION; RETREATMENT; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL STIMULATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXUDATES AND TRANSUDATES; FEMALE; HUMANS; INJECTIONS, INTRAOCULAR; MACULAR DEGENERATION; MALE; MIDDLE AGED; RETREATMENT; RETROSPECTIVE STUDIES; VISUAL ACUITY; VITREOUS BODY;

EID: 78651371501     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181de5609     Document Type: Article

References (16)

1. Ip MS, Scott IU, Brown GC, et al; American Academy of Ophthalmology. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology 2008;115:1837-1846.
2. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
3. Brown DM, Kaiser PK,Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
4. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-248.
5. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583.
6. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.
7. Kang S, Roh YJ. One-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroups. Jpn J Ophthalmol 2009;53: 389-395.
8. Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf- Schnurrbusch UE. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to agerelated macular degeneration. Am J Ophthalmol 2009;147: 831-837.
9. Cohen SY, Dubois L, Tadayoni R, et al. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 2009;148: 409-413.
10. Spaide RF. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 2007;143: 679-680.
11. Spaide RF. The as-needed treatment strategy for choroidal neovascularization: a feedback-based treatment system. Am J Ophthalmol 2009;148:1-3.
12. Engelbert M, Zweifel SA, Freund KB. Treat and extend dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina 2009;29:1424-1431.
13. Bottoni F, Massacesi A, Cigada M, Viola F, Musicco I, Staurenghi G. Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation. Arch Ophthalmol 2005;123: 1644-1650.
14. Boscia F, Parodi MB, Furino C, Reibaldi M, Sborgia C. Photodynamic therapy with verteporfin for retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol 2006;244: 1224-1232.
15. Freund KB, Klais CM, Eandi CM, et al. Sequenced combined intravitreal triamcinolone and indocyanine green angiographyguided photodynamic therapy for retinal angiomatous proliferation. Arch Ophthalmol 2006;124:487-492.
16. Hemeida TS, Keane PA, Dustin L, Sadda SR, Fawzi AA. Longterm visual and anatomic outcomes following anti-VEGF monotherapy for retinal angiomatous proliferation. Br J Ophthalmol October 23, 2009 [Epub ahead of print].